Risk indicators for development of headache during dipyridamole treatment after cerebral Ischaemia of arterial origin

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 80, Issue 4, 2009, Pages 437-439

  Halkes, P H A ^a,c   Van Gijn, J V ^a   Kappelle, L J ^a   Koudstaal, P J ^b   Algra, A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIPYRIDAMOLE; ANTITHROMBOCYTIC AGENT;

ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; STROKE; TRANSIENT ISCHEMIC ATTACK; AGED; BRAIN ARTERY; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; HEADACHE; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; ROC CURVE; SMOKING;

AGED; ASPIRIN; BRAIN ISCHEMIA; CEREBRAL ARTERIES; DIPYRIDAMOLE; DRUG THERAPY, COMBINATION; FEMALE; HEADACHE; HUMANS; HYPERTENSION; MALE; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; ROC CURVE; SEX FACTORS; SMOKING; STROKE;

EID: 64749116314     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2008.147918     Document Type: Article

References (8)

1. The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006;367:1665-73.
2. Chua C, Navarro J, San Luis A, et al. Tolerance study among Filipinos on acetylsalicylic acid and dipyridamole. Neurol J Southeast Asia 2003;8:9-13.
3. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
4. Meyers AM, Topham L, Ballow J, et al. Adverse reactions to dipyridamole in patients undergoing stress/rest cardiac perfusion testing. J Nucl Med Technol 2002;30:21-4.
5. Kruuse C, Jacobsen TB, Lassen LH, et al. Dipyridamole dilates large cerebral arteries concomitant to headache induction in healthy subjects. J Cereb Blood Flow Metab 2000;20:1372-9.
6. Lindgren A, Husted S, Staaf G, et al. Dipyridamole and headache-a pilot study of initial dose titration. J Neurol Sci 2004;223:179-84.
7. Theis JG, Deichsel G, Marshall S. Rapid development of tolerance to dipyridamoleassociated headaches. Br J Clin Pharmacol 1999;48:750-5.
8. Dresse A, Chevolet C, Delapierre D, et al. Pharmacokinetics of oral dipyridamole (Persantine) and its effect on platelet adenosine uptake in man. Eur J Clin Pharmacol 1982;23:229-34.rffrt 8. Dresse A, Chevolet C, Delapierre D, et al. Pharmacokinetics of oral dipyridamole (Persantine) and its effect on platelet adenosine uptake in man. Eur J Clin Pharmacol 1982; 23: 229-34.